Cover Image

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide

Background: HIV pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine is effective when taken daily. Previously, we developed a urine assay capable of detecting the prodrug tenofovir (TFV) in patients taking tenofovir disoproxil fumarate (TDF)-based PrEP. However, tenofovir alafenamide (TAF)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Linden Lalley-Chareczko (Author), Emily Hiserodt (Author), Ganesh Moorthy (Author), Athena Zuppa (Author), Karam Mounzer (Author), Helen Koenig (Author)
Format:	Book
Published:	Frontiers Media S.A., 2020-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
by: Aida N. Kawuma, et al.
Published: (2023)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
by: Andrew Hill, et al.
Published: (2018)

Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
by: Man Li, et al.
Published: (2023)

Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations
by: Li X, et al.
Published: (2021)

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
by: Laura Else, et al.
Published: (2022)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
by: Hannes Lengauer, et al.
Published: (2020)

Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
by: Emmanouil Sinakos, et al.
Published: (2024)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
by: Ashana Puri, et al.
Published: (2019)

Long-Term Evaluation of Changes in Kidney Function after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients Living with HIV
by: Jared M. Gilbert, et al.
Published: (2022)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
by: Manjula Gunawardana, et al.
Published: (2020)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
by: Lanqing Li, et al.
Published: (2023)

Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection
by: Ivana Massud, et al.
Published: (2024)

Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
by: Liu QM, et al.
Published: (2021)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023)

Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques
by: G. J. Gatto, et al.
Published: (2022)

Short-Term Efficacy of Tenofovir Alafenamide in Acute-On-Chronic Liver Failure: A Single Center Experience
by: Zhiqin Li, et al.
Published: (2024)

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide as maintenance treatment of patients with HIV and HBV co-infection
by: Y.-S. Huang, et al.
Published: (2019)

Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort
by: Aoife Lacey, et al.
Published: (2018)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
by: Linying Li, et al.
Published: (2020)

Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention
by: M. Melissa Peet, et al.
Published: (2024)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
by: Kensuke Abe, et al.
Published: (2024)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
by: Leah M. Johnson, et al.
Published: (2019)

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms
by: M. Satya Venkata Sakuntala, et al.
Published: (2021)

Evaluation of urinary excretion of dolutegravir or emtricitabine/tenofovir/elvitegravir/cobicistat antiretroviral-based regimens using plasma and urine trough concentration
by: Jérémy Lourenco, et al.
Published: (2018)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
by: Ranzenigo M, et al.
Published: (2022)

Tenofovir and Severe Symptomatic Hypophosphatemia
by: Asim Kichloo MD, et al.
Published: (2019)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
by: Ranzenigo M, et al.
Published: (2022)

Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant
by: Fernanda P. Pons-Faudoa, et al.
Published: (2020)

Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection
by: Jiapeng Li, et al.
Published: (2021)

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022)

Tough choices: Tenofovir, tenders and treatment
by: Nathan Ford, et al.
Published: (2008)

Tenofovir-associated bone density loss
by: Iwen F Grigsby, et al.
Published: (2009)

Application of High-Performance Liquid Chromatography for Simultaneous Determination of Tenofovir and Creatinine in Human Urine and Plasma Samples
by: Patrycja Olejarz, et al.
Published: (2020)

The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report
by: Yahya Ali Mohzari, et al.
Published: (2023)